News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
289,416 Results
Type
Article (15706)
Company Profile (58)
Press Release (273650)
Multimedia
Podcasts (126)
Webinars (13)
Section
Business (104049)
Career Advice (505)
Deals (15927)
Drug Delivery (120)
Drug Development (38179)
Employer Resources (50)
FDA (6856)
Job Trends (6562)
News (155762)
Policy (14759)
Tag
2027 BioCapital Standard (1)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (495)
Accelerated approval (28)
ADA (24)
Adcomms (13)
Allergies (102)
Alliances (23929)
ALS (79)
Alzheimer's disease (598)
Antibody-drug conjugate (ADC) (206)
Approvals (7205)
Artificial intelligence (330)
ASCO (119)
Autoimmune disease (94)
Automation (23)
Bankruptcy (157)
Best Places to Work (4615)
BIO (26)
BIOSECURE Act (10)
Biosimilars (172)
BioSpace Insights (72)
Biotechnology (30)
Bladder cancer (55)
Brain cancer (43)
Breast cancer (244)
Cancer (1956)
Cardiovascular disease (276)
Career advice (449)
Career pathing (15)
CAR-T (74)
CDC (12)
Cell therapy (231)
Cervical cancer (20)
Clinical research (33944)
Collaboration (1078)
Commercialization (2)
Company closure (1)
Compensation (429)
Complete response letters (60)
COVID-19 (828)
CRISPR (58)
C-suite (739)
Cystic fibrosis (66)
Data (2910)
Decentralized trials (2)
Denatured (22)
Depression (69)
Dermatology (17)
Diabetes (304)
Diagnostics (1637)
Digital health (22)
Diversity (4)
Diversity, equity & inclusion (14)
Drug discovery (193)
Drug pricing (179)
Drug shortages (32)
Duchenne muscular dystrophy (109)
Earnings (35347)
Editorial (38)
Employer branding (4)
Employer resources (47)
Events (41410)
Executive appointments (664)
FDA (8523)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (2)
Frontotemporal dementia (5)
Funding (670)
Gene editing (96)
Generative AI (41)
Gene therapy (233)
GLP-1 (931)
Government (1602)
Grass and pollen (4)
Guidances (188)
Healthcare (4078)
Hematology (66)
HIV (22)
Huntington's disease (14)
IgA nephropathy (59)
Immunology and inflammation (109)
Immuno-oncology (37)
Indications (111)
Infectious disease (932)
Inflammatory bowel disease (90)
Inflation Reduction Act (12)
Influenza (30)
Intellectual property (151)
Interviews (63)
IPO (6161)
IRA (44)
Job creations (2133)
Job search strategy (398)
JPM (40)
Kidney cancer (15)
Labor market (42)
Layoffs (249)
Leadership (14)
Legal (3568)
Licensing (3)
Liver cancer (29)
Longevity (10)
Lung cancer (270)
Lymphoma (170)
Machine learning (17)
Management (18)
Manufacturing (691)
Marketing (7)
MASH (116)
Medical affairs (1)
Medical device (1666)
Medtech (1691)
Mergers & acquisitions (10372)
Metabolic disorders (1085)
mRNA (80)
Multiple sclerosis (68)
NASH (17)
Neurodegenerative disease (149)
Neuropsychiatric disorders (57)
Neuroscience (1203)
Neurotech (1)
NextGen: Class of 2026 (1778)
Non-profit (700)
Now hiring (48)
Obesity (656)
Opinion (164)
Ovarian cancer (75)
Pain (145)
Pancreatic cancer (89)
Parkinson's disease (119)
Partnered (13)
Patents (307)
Patient recruitment (228)
Peanut (15)
People (30990)
Pharmaceutical (33)
Pharmacy benefit managers (22)
Phase 1 (8788)
Phase 2 (14289)
Phase 3 (12963)
Pipeline (4157)
Policy (196)
Postmarket research (1444)
Preclinical (3542)
Press Release (25)
Prostate cancer (128)
Psychedelics (31)
Radiopharmaceuticals (172)
Rare diseases (556)
Real estate (2771)
Recruiting (19)
Regulatory (12165)
Reports (17)
Research institute (619)
Resumes & cover letters (64)
Rett syndrome (14)
RNA editing (12)
RSV (25)
Schizophrenia (92)
Series A (147)
Series B (82)
Service/supplier (1)
Sickle cell disease (72)
Special edition (12)
Spinal muscular atrophy (93)
Sponsored (11)
Startups (1724)
State (2)
Stomach cancer (6)
Supply chain (89)
Tariffs (79)
The Weekly (101)
Vaccines (311)
Venture capital (57)
Weight loss (495)
Women's health (55)
Worklife (4)
Date
Today (35)
Last 7 days (230)
Last 30 days (762)
Last 365 days (11325)
2026 (6797)
2025 (11529)
2024 (13224)
2023 (14843)
2022 (20218)
2021 (20772)
2020 (19758)
2019 (15726)
2018 (12441)
2017 (14433)
2016 (13568)
2015 (15921)
2014 (12751)
2013 (10872)
2012 (11719)
2011 (12292)
2010 (11162)
Location
Africa (337)
Alabama (25)
Alaska (4)
Arizona (92)
Arkansas (5)
Asia (21691)
Australia (2800)
California (4350)
Canada (1924)
China (837)
Colorado (189)
Connecticut (173)
Delaware (181)
Europe (44384)
Florida (831)
Georgia (86)
Hawaii (2)
Idaho (12)
Illinois (499)
India (80)
Indiana (342)
Iowa (4)
Japan (389)
Kansas (87)
Kentucky (22)
Louisiana (11)
Maine (2)
Maryland (545)
Massachusetts (3489)
Michigan (73)
Minnesota (228)
Mississippi (1)
Missouri (42)
Montana (9)
Nebraska (12)
Nevada (21)
New Hampshire (12)
New Jersey (1954)
New Mexico (7)
New York (1210)
North Carolina (789)
North Dakota (2)
Northern California (2049)
Ohio (104)
Oklahoma (7)
Oregon (17)
Pennsylvania (912)
Puerto Rico (33)
Rhode Island (21)
South America (592)
South Carolina (13)
Southern California (1939)
Tennessee (84)
Texas (615)
United States (17140)
Utah (69)
Vermont (1)
Virginia (229)
Washington D.C. (43)
Washington State (331)
West Virginia (1)
Wisconsin (61)
Wyoming (1)
289,416 Results for "novo nordisk pharmaceuticals puerto rico".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Sickle cell disease
Agios axes next-gen sickle cell candidate after it fails to best Novo’s asset
Agios Pharmaceuticals’ sickle cell disease candidate didn’t prove any better than Novo Nordisk’s investigational PK activator or the biopharma’s own asset that is currently under FDA review for the indication.
July 21, 2026
·
2 min read
·
Gabrielle Masson
Immunology and inflammation
Novo’s late-stage IL-6 stumble shakes inflammation space
Novo Nordisk was banking on the inflammatory benefits of its investigational therapy ziltivekimab to improve cardiovascular outcomes. Last week’s Phase 3 failure dashed not just the Danish pharma’s hopes but that of other drugmakers working on the same pathway.
August 3, 2026
·
2 min read
·
Tristan Manalac
Manufacturing
Lilly Continues Manufacturing Push With $1.2B Puerto Rico Facility for GLP-1 Pill
The investment, which will expand Eli Lilly’s existing campus in Puerto Rico, is slated to create 100 new jobs, on top of around 1,000 construction-related roles.
October 30, 2025
·
2 min read
·
Tristan Manalac
Cardiovascular disease
Novo’s IL-6 inhibitor fails in cardiovascular Phase 3, plunging shares more than 9%
Novo Nordisk’s IL-6 inhibitor ziltivekimab failed to reduce the risk of cardiovascular events in the late-stage trial, dashing hopes for an edge in the hyper-competitive cardiometabolic space.
July 31, 2026
·
2 min read
·
Michael Gibney
Press Releases
Novo Nordisk A/S - share repurchase programme - July 27, 2026
July 27, 2026
·
2 min read
Legal
Novo ordered to face CagriSema fraud claims from shareholders: New Jersey court
Shareholders allege that Novo Nordisk withheld information about crucial protocol changes in a Phase 3 study of the weight loss drug CagriSema, which led investors to buy company shares “at artificially inflated prices.”
July 29, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Fangzhou Launches Novo Nordisk’s Once-Weekly Basal Insulin/GLP-1 Therapy in China
July 19, 2026
·
3 min read
Press Releases
Novo Nordisk A/S - share repurchase programme - July 20, 2026
July 20, 2026
·
2 min read
Earnings
Novo’s Wegovy pill reaches 1M patients, shattering expectations with $355M in sales
Analysts and investors alike had been eagerly awaiting sales figures for Novo Nordisk’s Wegovy pill. The answer blew past expectations by 86%.
May 6, 2026
·
4 min read
·
Annalee Armstrong
Sickle cell disease
Novo’s late-stage sickle cell win piles pressure on competitors
Novo Nordisk’s etavopivat elicited a 27% drop in vaso-occlusive crises and 48.7% hemoglobin response after 24 weeks, creating “separation amongst PK class candidates,” Truist analysts said on Monday. Novo plans to seek FDA approval in the back half of 2026.
April 20, 2026
·
2 min read
·
Tristan Manalac
1 of 28,942
Next
